Why Biotech Stocks Are So Volatile

Introduction

Biotech and pharmaceutical company stocks are among the most volatile in the market, particularly those with smaller market capitalizations. Unlike other industries, valuations in this sector can swing dramatically based on binary events such as clinical trial outcomes, FDA approval decisions, or even the progress of competing therapies. This article will explore the key drivers behind this volatility and explain why biotech stocks are so sensitive to new developments.

How clinical trial results drive biotech stock volatility.

The financial future of a biotech company often relies heavily on a small number of late-stage pipeline drugs. Whether the company can generate significant future revenue is largely determined by the outcomes of clinical trials and the results of FDA regulatory reviews for these critical assets. Positive trial data or FDA approval can create substantial upside, while failures or FDA rejection often led to sharp declines in biotech stock valuations.

1. Significant upfront investment and low probability of success

Drug development is an extremely expensive and time-consuming process, as shown in a JAMA study on U.S. research and development costs (1). The analysis estimated that developing a single new drug required an average of over $170 million, but when accounting for failed programs and capital costs, the total investment often exceeded $800 million. At the same time, the overall probability of success is low, which is roughly about 12.8% of drugs advancing from clinical trials to eventual FDA approval (2). This combination of massive upfront spending and limited success rates underscores why biotech stocks are so volatile: a single failure can erase years of investment, while success may generate outsized returns.

Thus, sudden spikes of buying and selling often occur when a company releases Phase 2 or Phase 3 trial results for its key pipeline drugs, since most failures happen at these stages. Positive data at Phase 2 or Phase 3 is especially significant because it not only signals higher chances of eventual FDA approval but also suggests stronger future financial performance, particularly when the drug targets a large patient population with limited or no effective treatment.

2. FDA approval and regulatory risk

Unlike other industries where revenues are driven by ongoing operations or market share, in biotech the ability to commercialize a drug is entirely determined by regulatory approval. As a result, FDA decisions are among the most powerful drivers of biotech stock volatility. Under the Prescription Drug User Fee Act (PDUFA), the FDA sets specific deadlines for reviewing New Drug Applications (NDAs) and Biologics License Applications (BLAs). When a company receives FDA approval, the market typically prices in the potential revenue increase from launching the drug. Conversely, if the FDA issues a Complete Response Letter (CRL), the company's stock price often suffers an immediate and severe decline.

Moreover, discussions between the FDA and a company—whether about trial data, safety concerns, or even labelling issues can quickly unsettle investors. Ongoing updates from the FDA often trigger sharp swings in biotech stock prices, as the market reacts to even small signals about the likelihood of approval or delay.

Take ImmunityBio as an example. The FDA issued a CRL regarding the BLA for N-803 (Anktiva) in combination with Bacillus Calmette-Guérin (BCG). In the days leading up to the PDUFA date, the company’s stock surged for three consecutive sessions—up 15.5% on May 4, 2023, 43.1% on May 5, and 15.7% on May 6. Investors were so confident in the evidence supporting approval that they drove the share price from $3.40 to $5.60 even before any FDA decision was announced. However, after the CRL was issued, the stock price collapsed by 54% in a single day based on the company's SEC filings. Over the seven trading days from May 4 to May 12, ImmunityBio's stock exhibited volatility of nearly 38%, representing a highly significant price movement.

3. Cash Runway Pressure on Biotech company

Unlike established pharmaceutical companies that benefit from steady product sales, most biotechs are pre-revenue and must finance their operations almost entirely through external funding, which leads to very high cash burn rates. Analysis of SEC filings across U.S. biotech firms shows that median quarterly burn rates for pre-revenue companies often exceed $30–50 million, and the costs rise substantially as late-stage clinical trials move forward (4). Investors therefore focus heavily on the company’s cash runway, a measure of how long it can operate before running out of capital, typically calculated as cash on hand divided by the quarterly burn rate. A runway shorter than 12 months often triggers concerns that the firm will soon need to raise additional funds, usually through equity offerings that dilute existing shareholders. This liquidity pressure contributes directly to stock volatility: announcements of trial delays or unexpected expenses can shorten the runway and drive selloffs, while positive developments such as licensing deals or milestone payments can extend the runway and lift valuations.

Conclusion

Biotech stocks are highly volatile because their value depends on three main factors: clinical trial outcomes, FDA approval decisions, and cash runway strength. Positive data or approvals can create substantial upside, while failed trials, regulatory setbacks, or liquidity pressures often lead to sharp declines. These forces combined make biotech a high-risk, high-reward sector where investors must closely track both scientific progress and financial stability.

Key takeaways

Q1: Why are biotech stocks so volatile?

Biotech stocks are volatile because valuations depend heavily on clinical trial results, FDA approval decisions, and company cash runway.

Q2: How do clinical trials affect biotech stock prices?

Most drug failures occur in Phase 2 and Phase 3 trials, so positive data can boost valuations sharply, while failed trials often cause steep declines.

Q3: What role does the FDA play in biotech stock volatility?

FDA approvals, PDUFA dates, and Complete Response Letters act as binary events that can immediately raise or lower stock prices.

Q4: Why does cash runway matter for biotech companies?

High burn rates mean many biotech companies rely on external financing; a short runway increases the risk of dilution and drives investor uncertainty.

Q5: What should investors watch to understand biotech stock volatility?

Investors should track clinical data readouts, FDA regulatory updates, and liquidity metrics together to gauge risks and opportunities.

References

1. Costs of drug development and R&D intensity in the US (2000–2018)
2. Approval success rates of drug candidates by target and modality
3. NDA and BLA approvals
4. Measuring the return from pharmaceutical innovation (2022)